


**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Berka et al.

Serial No.: 09/482,788

Filed: January 13, 2000



Group Art Unit: To Be Assigned

Examiner: To Be Assigned

For: Methods For Producing Polypeptides In Cyclohexadepsipeptide-Deficient Cells

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:


1. Shemyakin et al., 1969, *Journal of Membrane Biology* 1: 402-430
2. Reper et al., 1995, *European Journal of Biochemistry* 230: 119-126
3. Grove and Pople, 1980, *Mycopathologia* 70: 103-105
4. Haese et al., 1993, *Molecular Microbiology* 7: 905-914
5. Herrmann et al., 1996, *Molecular Plant-Microbe Interactions* 9: 226-232

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of the application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b). Therefore, no fee is due.

Respectfully submitted,

Date: April 11, 2000

  
\_\_\_\_\_  
Robert L. Starnes, Reg. No. 41,324  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

Attorney Docket No.: 5778.200-US



1652

PATENT

#4  
J.G.J  
4/28/00

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Berka et al.

Serial No.: 09/482,788

Group Art Unit: To Be Assigned

Filed: January 13, 2000

Examiner: To Be Assigned

For: Methods For Producing Polypeptides In Cyclohexadepsipeptide-Deficient Cells

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Box DD  
Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Transmittal of Information Disclosure Statement (in duplicate)
2. Information Disclosure Statement
3. PTO-1449 Form
4. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner of Patents and Trademarks  
Washington, DC 20231

on April 11, 2000.

Seleste A. Buriani  
(name of person mailing paper)

Seleste A. Buriani  
(signature of person mailing paper)

RECEIVED  
APR 19 2000  
TC 1600 MAIL ROOM

Attorney Docket No.: 5778.200-US



PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Berka et al.

Serial No.: 09/482,788

Group Art Unit: To Be Assigned

Filed: January 13, 2000

Examiner: To Be Assigned

For: Methods For Producing Polypeptides In Cyclohexadepsipeptide-Deficient Cells

RECEIVED  
U.S. PATENT & TRADEMARK OFFICE  
APR 19 2000  
MAIL ROOM


**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

Transmitted herewith is an Information Disclosure Statement for the above-identified application. Should it be determined that a fee is due, please charge it to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,



Robert L. Starnes, Reg. No. 41,324  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, New York 10017  
(212) 867-0123

Date: April 11, 2000